Skip to main content
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. — Investor Relations & Filings

Ticker · ENSC ISIN · US2936021086 US Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2026-05-22 Delisting Announcement
Country US United States of America
Listing US ENSC

About Ensysce Biosciences, Inc.

https://ensysce.com/

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company developing solutions for severe pain relief, with a focus on stemming the prescription drug abuse epidemic. The company utilizes proprietary prodrug technology platforms to create safer prescription drugs. Its lead product candidate, PF614, is a next-generation opioid designed with Trypsin-Activated Abuse Protection (TAAP™) to deter abuse via injection or inhalation. PF614 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). Ensysce is also developing its Multi-Pill Abuse Resistance (MPAR®) technology, an overdose protection platform designed to prevent respiratory depression when multiple doses are consumed. The company's goal is to provide effective pain management while reducing the potential for misuse, abuse, and overdose.

Recent filings

Filing Released Lang Actions
8-K
Delisting Announcement Classification · 95% confidence The document is a U.S. SEC Form 8-K reporting Item 3.01: Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard. It details receipt of Nasdaq’s notice of non-compliance and the company’s plan submission to avoid delisting. This clearly falls under a Delisting Announcement.
2026-05-22 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K “Current Report” filed pursuant to the Securities Exchange Act of 1934, specifically under Item 2.02 “Results of Operations and Financial Condition,” announcing a press release with the company’s financial results for the fiscal quarter ended March 31, 2026. It is an initial quarterly earnings announcement rather than a full annual or interim report, so it matches the definition of an Earnings Release (Code: ER). Q1 2026
2026-05-15 English
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text includes details about an amendment to the Articles of Incorporation (Certificate of Correction to Certificate of Designation of Series B Preferred Stock). It is not a full financial report, earnings release, or management discussion. The document is relatively short (3905 characters) and contains specific event disclosure rather than comprehensive financial data. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2026-03-23 English
8-K - ENSYSCE BIOSCIENCES, INC. (0001716947) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 27, 2026, reporting a notice of deficiency from Nasdaq regarding the company's failure to meet the minimum bid price requirement for continued listing. The content focuses on the delisting risk and compliance timeline with Nasdaq listing rules. This is a regulatory announcement about potential delisting, not a full financial report or earnings release. The key phrase 'Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard' and the detailed explanation of Nasdaq's deficiency letter confirm this is a Delisting Announcement.
2026-02-27 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 8, 2026, reporting on the submission of matters to a vote of security holders at the company's annual meeting held on January 7, 2026. It details the voting results on several proposals including stock issuance approval, amendment of an incentive plan, election of directors, and ratification of the independent auditor. The content is focused on official results from shareholder votes at a general meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 4869 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2026-01-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.